Method and compositions for the diagnosis and treatment of non-small cell lung cancer using gene expression profiles
CA 2480045 C · Owner: Demuth, Jeffrey P. · Inventors: Willey, James C.; Graves, Timothy G.; Crawford, Erin L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention identifies and quantifies changes in gene expression associated with non-small cell lung cancer NSCLC by examining gene expression in tissue from normal lung and diseased lung. The present invention also identifies and quantifies expression profiles which serve as useful diagnostic markers as well as markers that are useful to monitor disease states disease , progression, drug toxicity, drug efficacy and drug metabolism.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 27, 2003 and granted September 24, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 27, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 27, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.